Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. News
  7. Summary
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Polyphor AG signed a merger agreement to acquire EnBiotix, Inc.

09/01/2021 EDT

Polyphor AG (SWX:POLN) signed a merger agreement to acquire EnBiotix, Inc. on September 1, 2021. Pursuant to the agreement, Polyphor acquires all of the outstanding capital stock of EnBiotix in exchange for newly issued shares of Polyphor common stock. Upon completion of the merger, former EnBiotix equity holders (including investors of the planned financing round) are expected to own approximately 74-77% of Polyphor's common stock. Polyphor's current shareholders are expected to own approximately 23-26% of Polyphor's issued common shares following the closing of the merger. In a related transaction, EnBiotix agreed to acquire Inhaled Murepavadin at an agreed valuation of $10 million in exchange for 2,599,655 of common shares of EnBiotix. Additionally, prior to closing EnBiotix expects to finalize a financing round. Following closing, Polyphor will be renamed and is expected to trade under a new ticker symbol on the Swiss Stock Exchange. Upon completion of the merger, Jeffrey D. Wager, currently Chairman and Chief Executive Officer of EnBiotix, is expected to become Chairman of the Board of Directors and Chief Executive Officer of the combined company replacing the current Chief Executive Officer, Gökhan Batur, who will oversee the next steps until the closing of the merger. Andreas Wallnöfer, Silvio Inderbitzin and Hugh O'Dowd will resign as Board members. Kuno Sommer and Bernard Bollag, current members of the Board of Directors of Polyphor, will remain as Board members. Dennis Ausiello, Dan Hartman and Robert Clarke, current members of the Board of Directors of EnBiotix, are nominated as new members the Board of Directors of the combined company. Hernan Levett, Polyphor's current Chief Financial Officer, will continue as Chief Financial Officer of the combined company. Upon completion of the merger Juergen Froehlich, Chief Medical Officer at EnBiotix, is replacing Frank Weber, who has decided to leave Polyphor end of October 2021 to pursue other career opportunities. Daniel Obrecht, Chief Scientific Officer of Polyphor, will retire from the company by end of 2021 as planned and continue to serve as a scientific consultant to the merged company. The transaction is subject to a number of closing conditions, including approval by Polyphor and EnBiotix shareholders, satisfactory completion of due diligence and satisfactory assessment of tax consequences. The transaction has been unanimously approved by the board of directors of both companies and is expected to close in Q4 2021.


© S&P Capital IQ 2021
All news about POLYPHOR AG
10/15POLYPHOR : Exempted From Public Tender Offer Obligation In Merger With EnBiotix
MT
10/15La Commission des OPA constate l'absence d'obligation de présenter une offre publique d..
DJ
10/15Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer ..
DJ
10/14Polyphor to Seek Acquisitions
CI
09/27Polyphor publishes invitation to Extraordinary General Meeting and announces financial ..
DJ
09/27Polyphor AG Announces Executive Changes
CI
09/10POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
09/10Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by ..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01POLYPHOR : Signs All-Stock Merger Deal With Rare Disease Company EnBiotix
MT
More news
Financials
Sales 2021 1,00 M 1,09 M 1,09 M
Net income 2021 -41,4 M -45,2 M -45,2 M
Net Debt 2021 76,8 M 83,8 M 83,8 M
P/E ratio 2021 -0,47x
Yield 2021 -
Capitalization 21,6 M 23,5 M 23,5 M
EV / Sales 2021 98,4x
EV / Sales 2022 5,65x
Nbr of Employees 52
Free-Float 82,3%
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 1,75 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Gökhan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Daniel Obrecht Chief Scientific Officer
Frank T. Weber Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
POLYPHOR AG-78.50%24
CSL LIMITED4.05%100 550
WUXI BIOLOGICS (CAYMAN) INC.10.02%61 723
SAMSUNG BIOLOGICS CO.,LTD.5.08%48 773
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.8.87%40 270